Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Polycystic Ovary Syndrome 4Inflammation 2Urinary Tract Infections 1Staphylococcal Infections 1Spasm 1Sleep Initiation and Maintenance Disorders 1Skin Diseases 1Sepsis 1Seizures 1Schizophrenia, Treatment-Resistant 1Schizophrenia 1Retinitis 1Renal Insufficiency, Chronic 1Rare Diseases 1Pulmonary Arterial Hypertension 1Pneumonia 1Pain 1Neutropenia 1Migraine Disorders 1Metabolic Syndrome 1Menorrhagia 1Meningitis, Bacterial 1Meningitis 1Intraabdominal Infections 1Influenza, Human 1Infections 1Hypokalemia 1Hypertension 1Hyperandrogenism 1Hyperaldosteronism 1

Interventions

tipifarnib 1soybean oil, phospholipid emulsion 1Sunscreening Agents 1Spironolactone 1Sorafenib 1Methods 1Hydrocortisone 1Genetic Testing 1Genetic Counseling 1Fat Emulsions, Intravenous 1Educational Status 1Early Intervention, Educational 1Doxycycline 1Counseling 1Acetates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Malignant Neoplasm × Spironolactone × Clear all
NCT01867294 2020-01-09

Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab

Academic and Community Cancer Research United

Phase 2 Completed
19 enrolled 9 charts
Other neoplasm

Advanced Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡